Chronic Kidney Disease (CKD)
Conditions
Interventions
oral administration of Azilsartan once in the morning
Sponsors
Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. received medical care at Nagoya City University Hospital 2. UNaV of 85-120mmol/day at least 3 different times 4 wks before enrollement 3. CKD criteria based on K/DOQI 4. need for Azilsartan 5. documented informed concent
Exclusion criteria
Exclusion criteria: 1. previous treatment with ARB, or diuretics 2 months before enrollment 2. change in the antihypertensive medication 2 months before enrollment 3. contraindication to Azilsartan (history of allergic reaction to it, bilateral renal artery stenosis) 4. presence or possibility of pregnancy/lactation 5. HbA1c >9.0 % 6. GOT >100, or GPT >85 7. endocrine hypertension 8. accelerated o r malignant hypertension (progressive renal dysfunction with diastolic BP of >120-130 mmHg 9. serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases 10. nephrotic syndrome (serum albumin <2.5 g/dl) 11. any reason for ineligibility suggested by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate whether night/day UNaV ratio reduce to <1.0 before the night/day BP ratio reduce to <0.9 | — |
Secondary
| Measure | Time frame |
|---|---|
| GFR, Urinary excretion of albumin, potassium, chrolide, angiotensinogen and 8-OHdG, HF and LF/HF obtained by Holter ECG,safety Circadian BP rhythm 1 year after treatment was also studied. | — |
Countries
Japan
Contacts
Public ContactMichio FUKUDA
Nagoya City University Hospital Division of Nephrology
Outcome results
None listed